Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo

Desvaux, Emiko; Courteau, Alan; Bellaye, Pierre-Simon; Guillemin, M.; Drouet, Camille; Walker, Paul; Collin, Bertrand; Decréau, Richard A.

doi:10.1186/s13550-018-0464-7

Cited by 9 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pimonidazole, a compound which specifically accumulates in cells in hypoxic conditions, was found to accumulate in alveolar epithelial cells boarding fibrotic lung areas upon BLM in mice. Several hypoxia-sensing probes have been extensively studied in cancer and are now evaluated in preclinical and clinical settings as tracers for hypoxia imaging including 18 F-fluoromisonidazole ([ 18 F]FMISO [16]). Whether tracers of tissue hypoxia may be useful for lung fibrosis monitoring remains unstudied and preclinical data evaluating [ 18 F]FMISO PET in lung fibrosis are desperately missing.…”

Section: Introductionmentioning

confidence: 99%

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach

Tanguy

Goirand

Bouchard

et al. 2021

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Purpose Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor outcome and limited therapeutic options. Imaging of IPF is limited to high-resolution computed tomography (HRCT) which is often not sufficient for a definite diagnosis and has a limited impact on therapeutic decision and patient management. Hypoxia of the lung is a significant feature of IPF but its role on disease progression remains elusive. Thus, the aim of our study was to evaluate hypoxia imaging with [18F]FMISO as a predictive biomarker of disease progression and therapy efficacy in preclinical models of lung fibrosis in comparison with [18F]FDG. Methods Eight-week-old C57/BL6 mice received an intratracheal administration of bleomycin (BLM) at day (D) 0 to initiate lung fibrosis. Mice received pirfenidone (300 mg/kg) or nintedanib (60 mg/kg) by daily gavage from D9 to D23. Mice underwent successive PET/CT imaging at several stages of the disease (baseline, D8/D9, D15/D16, D22/D23) with [18F]FDG and [18F]FMISO. Histological determination of the lung expression of HIF-1α and GLUT-1 was performed at D23. Results We demonstrate that mean lung density on CT as well as [18F]FDG and [18F]FMISO uptakes are upregulated in established lung fibrosis (1.4-, 2.6- and 3.2-fold increase respectively). At early stages, lung areas with [18F]FMISO uptake are still appearing normal on CT scans and correspond to areas which will deteriorate towards fibrotic lesions at later timepoints. Nintedanib and pirfenidone dramatically and rapidly decreased mean lung density on CT as well as [18F]FDG and [18F]FMISO lung uptakes (pirfenidone: 1.2-, 2.9- and 2.6-fold decrease; nintedanib: 1.2-, 2.3- and 2.5-fold decrease respectively). Early [18F]FMISO lung uptake was correlated with aggressive disease progression and better nintedanib efficacy. Conclusion [18F]FMISO PET imaging is a promising tool to early detect and monitor lung fibrosis progression and therapy efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach

Tanguy

Goirand

Bouchard

et al. 2021

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…They obtained acceptable iodine levels at the pancreatic tumour site on 124 I‐PET images and a therapeutic response in keeping with the imaging data 105 . Cerenkov luminescence (CLI) is the ability of certain radionuclides to emanate light, known as the Cerenkov effect 107 . This can be utilised in medical imaging through detection with an optical imaging (OI) device.…”

Section: Introductionmentioning

confidence: 56%

Use of radioiodine in nuclear medicine—A brief overview

Ferris

Carroll

Jenner³

et al. 2020

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Radioiodines have a long history in nuclear medicine. Herein, we discuss the production, properties and applications of these versatile iodine‐based imaging and theragnostic agents. There are 38 isotopes of iodine (I) including one stable form (127I). The most common radionuclides used in medical imaging and treatment, including Iodine‐123 (123I), Iodine‐124 (124I), Iodine‐125 (125I) and Iodine‐131 (131I), are discussed in this review.

show abstract

“…Cerenkov luminescence imaging (CLI) is based on the detection of visible photons emitted by Cerenkov radiation. Cerenkov luminescence is emitted when a charged particle traverses a dielectric medium with a velocity greater than the phase velocity of light in the medium (310)(311)(312). CLI has been performed to optically monitor the biodistribution of 32 P-ATP labeled T lymphocytes, in small rodents, in vivo (313,314).…”

Section: Optical Detection Techniquesmentioning

confidence: 99%

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors

et al. 2021

View full text Add to dashboard Cite

In recent years, cancer immunotherapy experienced remarkable developments and it is nowadays considered a promising therapeutic frontier against many types of cancer, especially hematological malignancies. However, in most types of solid tumors, immunotherapy efficacy is modest, partly because of the limited accessibility of lymphocytes to the tumor core. This immune exclusion is mediated by a variety of physical, functional and dynamic barriers, which play a role in shaping the immune infiltrate in the tumor microenvironment. At present there is no unified and integrated understanding about the role played by different postulated models of immune exclusion in human solid tumors. Systematically mapping immune landscapes or “topographies” in cancers of different histology is of pivotal importance to characterize spatial and temporal distribution of lymphocytes in the tumor microenvironment, providing insights into mechanisms of immune exclusion. Spatially mapping immune cells also provides quantitative information, which could be informative in clinical settings, for example for the discovery of new biomarkers that could guide the design of patient-specific immunotherapies. In this review, we aim to summarize current standard and next generation approaches to define Cancer Immune Topographies based on published studies and propose future perspectives.

show abstract

Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo

Cited by 9 publications

References 17 publications

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach

[18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach

Use of radioiodine in nuclear medicine—A brief overview

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors

Contact Info

Product

Resources

About